{"created":"2014-10-31T00:00:20+00:00","modified":"2015-05-14T17:26:47+00:00","valid":{"from":"2014-10-30T18:43:02+00:00","to":"3014-10-30T18:43:02+00:00"},"hreflang":"en","guid":"43954f8b-6360-49be-822e-303eb3f6aaf1","description":"HHS is paying for expedited drug research on Ebola.","itags":["Marketplace for Thursday October 30, 2014","PMP:Marketplace_PMP","Marketplace","43954f8b63609be922ea303eb3f6aaf1"],"teaser":"HHS is paying for expedited drug research on Ebola.","contenttemplated":"[{\"type\":\"text/html\",\"content\":\"<p><span>For five years, John Eldridge and his team at</span> <a href=\\\"http://www.profectusbiosciences.net/index.html\\\">Profectus Bioscience</a> <span>have developed and tested their Ebola vaccine. </span><span>First it was on guinea pigs, then monkeys. </span></p>\"},{\"type\":\"text/html\",\"content\":\"<p><span>At that point, Eldridge realized monkeys weren&apos;t getting sick.</span></p>\"},{\"content\":\"<p>“When I saw those results, I realized that we had a real vaccine candidate which had the potential to make a real difference for mankind,” he says.</p>\",\"type\":\"text/html\"},{\"content\":\"<p>But before it can go to market, the vaccine must be tested on humans, a timely and expensive proposition for tiny start-ups like Profectus. <span>And this is where things get tricky. </span><span>Despite this year’s outbreak, there is virtually no commercial market for Eldridge’s vaccine. </span><span>In other words, it’s financially difficult for a drug maker of any size to justify the expense of development and production with little payout in return.</span></p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>That’s why the little agency no one has ever heard of <span> –</span> the Biomedical Advanced Research and Development Authority (<a href=\\\"http://www.phe.gov/about/barda/Pages/default.aspx\\\">BARDA</a>) – is so important.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>“They are investing in things that would die if they didn’t have additional funding,” says Boston University’s <a href=\\\"http://www.bu.edu/law/faculty/profiles/bios/full-time/outterson_k.html\\\">Kevin Outterson</a>. </p>\"},{\"content\":\"<p>Outterson says getting any product from the lab to the market is called &quot;crossing the valley of death.&quot; <span>For products like Eldridge’s, which has little financial appeal but huge public health upside, that valley is deeper and longer.</span></p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>“You can think of BARDA almost like a venture capital firm buried in the U.S. government,” he says.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>To find an Ebola treatment, BARDA is investing in the most promising drugs and vaccines. <span>That money, about $30 million just for vaccines so far, changes the equation so it makes better business sense for companies big and small to bring drugs to market. </span><span>Unlike venture capitalists, BARDA won’t take a cut; in fact, more money may be on the way, with the President expected to seek additional funding from Congress.</span></p>\"},{\"content\":\"<p>“When we decided to put our pedal to the metal, everybody could accelerate and get to a finish line we are aiming for,” says <a href=\\\"http://www.hhs.gov/about/foa/osleadership/aspr.html\\\">Dr. Nicole Lurie</a>, assistant secretary for preparedness and response at HHS, who oversees BARDA.</p>\",\"type\":\"text/html\"},{\"content\":\"<p>She says vaccine development would usually take up to 10 years. “We are moving forward in unprecedented speed.”</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>With this Ebola crisis, Lurie says Washington and industry are hand-in-glove. <span>Lurie’s hoping to avoid mistakes from the</span> <a href=\\\"http://www.ncbi.nlm.nih.gov/pubmed/21342903\\\">2009 H1N1 pandemic</a><span>, when nearly 61 million Americans got sick and the virus killed more than 12,000 <span>–</span> all while the government, working with drug makers, couldn’t get enough flu vaccine</span> <a href=\\\"http://www.nejm.org/doi/full/10.1056/NEJMra1208802\\\">manufactured</a><span>.</span></p>\"},{\"content\":\"<p>“We learned that we needed much stronger relationships with our industry partners,” says Lurie.</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>She sees signs of a massive Ebola manufacturing mobilization, f<span>rom giants like GlaxoSmithKline to the little guys like Profectus and John Eldridge, who says he’s actually been given enough money to do the work this time.</span></p>\"},{\"type\":\"text/html\",\"content\":\"<p>“We negotiated the contract. They came to us multiple times and said, ‘we need to supply you with adequate funding that you can move as rapidly as possible,’” he says.</p>\"},{\"type\":\"text/html\",\"content\":\"<p>Eldridge still doesn’t know if his vaccine works. <span>But thanks to the tiny office no one has ever heard of, there’s a chance.</span></p>\"}]","byline":"D Gorenstein","contentencoded":"<div class=\"barn-cleaned\"><p><span>For five years, John Eldridge and his team at</span> <a href=\"http://www.profectusbiosciences.net/index.html\">Profectus Bioscience</a> <span>have developed and tested their Ebola vaccine.&nbsp;</span><span>First it was on guinea pigs, then monkeys.&nbsp;</span></p>\n<p><span>At that point, Eldridge realized monkeys weren't getting sick.</span></p>\n<p>“When I saw those results, I realized that we had a real vaccine candidate which had the potential to make a real difference for mankind,” he says.</p>\n<p>But before it can go to market, the vaccine must be tested on humans, a timely and expensive proposition for tiny start-ups like Profectus.&nbsp;<span>And this is where things get tricky.&nbsp;</span><span>Despite this year’s outbreak, there is virtually no commercial market for Eldridge’s vaccine.&nbsp;</span><span>In other words, it’s financially difficult for a drug maker of any size to justify the expense of development and production with little payout in return.</span></p>\n<p>That’s why the little agency no one has ever heard of <span>&nbsp;–</span>&nbsp;the Biomedical Advanced Research and Development Authority (<a href=\"http://www.phe.gov/about/barda/Pages/default.aspx\">BARDA</a>) – is so important.</p>\n<p>“They are investing in things that would die if they didn’t have additional funding,” says Boston University’s <a href=\"http://www.bu.edu/law/faculty/profiles/bios/full-time/outterson_k.html\">Kevin Outterson</a>.&nbsp;</p>\n<p>Outterson says getting any product from the lab to the market is called \"crossing the valley of death.\"&nbsp;<span>For products like Eldridge’s, which has little financial appeal but huge public health upside, that valley is deeper and longer.</span></p>\n<p>“You can think of BARDA almost like a venture capital firm buried in the U.S. government,” he says.</p>\n<p>To find an Ebola treatment, BARDA is investing in the most promising drugs and vaccines.&nbsp;<span>That money, about $30 million just for vaccines so far, changes the equation so it makes better business sense for companies big and small to bring drugs to market.&nbsp;</span><span>Unlike venture capitalists, BARDA won’t take a cut; in fact, more money may be on the way, with the President expected to seek additional funding from Congress.</span></p>\n<p>“When we decided to put our pedal to the metal, everybody could accelerate and get to a finish line we are aiming for,” says&nbsp;<a href=\"http://www.hhs.gov/about/foa/osleadership/aspr.html\">Dr. Nicole Lurie</a>, assistant secretary for preparedness and response at HHS, who oversees BARDA.</p>\n<p>She says vaccine development would usually take up to 10 years. “We are moving forward in unprecedented speed.”</p>\n<p>With this Ebola crisis, Lurie says Washington and industry are hand-in-glove.&nbsp;<span>Lurie’s hoping to avoid mistakes from the</span> <a href=\"http://www.ncbi.nlm.nih.gov/pubmed/21342903\">2009 H1N1 pandemic</a><span>, when nearly 61 million Americans got sick and the virus killed more than 12,000 <span>–</span>&nbsp;all while the government, working with drug makers, couldn’t get enough flu vaccine</span> <a href=\"http://www.nejm.org/doi/full/10.1056/NEJMra1208802\">manufactured</a><span>.</span></p>\n<p>“We learned that we needed much stronger relationships with our industry partners,” says Lurie.</p>\n<p>She sees signs of a massive Ebola manufacturing mobilization, f<span>rom giants like GlaxoSmithKline to the little guys like Profectus and John Eldridge, who says he’s actually been given enough money to do the work this time.</span></p>\n<p>“We negotiated the contract. They came to us multiple times and said, ‘we need to supply you with adequate funding that you can move as rapidly as possible,’” he says.</p>\n<p>Eldridge still doesn’t know if his vaccine works.&nbsp;<span>But thanks to the tiny office no one has ever heard of, there’s a chance.</span></p></div>","published":"2014-10-30T18:43:02+00:00","title":"BARDA: The venture capital firm buried in the U.S. government","tags":["Health Care","APM","Ebola","Ebola vaccine","BARDA"],"audio":[{"meta":{"height":"340","width":"610","crop":"primary"},"href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/457313240.jpg?itok=xRwu--rQ","type":"image/jpeg"},{"type":"audio/mpeg","href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2014/10/30/mp_20141030_seg_19_64.mp3","meta":{"duration_hms":"00:03:22","api":{"href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2014/10/30/mp_20141030_seg_19","type":"application/json"},"duration":202},"format":"MP3"}]}